C ALCITONIN (CT) IS a 32-amino acid hormone synthesized and secreted by the parafollicular cells of the thyroid gland. CT acts primarily on bone and kidney to reduce plasma Ca 2ϩ levels by inhibiting bone resorption and promoting Ca 2ϩ excretion. Therefore, CT is administered therapeutically in the treatment of diseases characterized by high bone turnover, including Paget's disease of bone, malignancy-associated hypercalcemia, and osteoporosis (1) . Mice homozygous for knockout of CALC I (the gene encoding CT and CT gene-related peptide) develop osteopenia, indicating a role for CT in skeletal homeostasis in vivo (2) .
The CT receptor (CTR), a G protein-coupled receptor, has been identified in a number of tissues, and the existence of splice variants has been reported (3) . The most common isoform of the CTR, C1a, was originally cloned from porcine kidney (4) and is also expressed in human, mouse, rat, and rabbit cells (5) (6) (7) (8) (9) (10) . A novel isoform in rabbit, CTR⌬e13, is generated by deletion of exon 13 during mRNA processing, resulting in the absence of 14 amino acid residues in the putative 7th transmembrane spanning domain. This deletion reduces the affinity of the CTR⌬e13 isoform for CT. The dissociation constant (K d ) for binding of salmon CT to the CTR⌬e13 isoform is 9 nm, whereas the K d for the C1a isoform is 0.2 nm (10) . Both isoforms activate adenylyl cyclase, leading to production of cAMP and activation of PKA. In contrast, only the C1a isoform couples to G q , activating PLC, which in turn leads to Ca 2ϩ mobilization and activation of PKC. It has been suggested that CT-induced elevations in cAMP and cytosolic free Ca 2ϩ concentration ([Ca 2ϩ ] i ) have two separate effects on osteoclasts: abolition of cell motility, and induction of cellular retraction, respectively (11) . Studies have shown that in addition to G s and G q , the C1a isoform couples to G i , and that the inhibition of adenylyl cyclase by G i is negatively regulated by PKC (12) . The C1a isoform induces Shc phosphorylation and Erk1/2 activation by mechanisms involving G i , PKC, and cytosolic Ca 2ϩ (13) . Expression of C1a and CTR⌬e13 isoforms vary in a tissuespecific manner, with CTR⌬e13 accounting for less that 15% of the total CTR mRNA in rabbit osteoclasts, kidney, and brain, but comprising at least 50% of the transcripts in skeletal muscle and lung (10) . Characterization of the signaling pathways activated by these two receptor isoforms is crucial for understanding the function of these receptors in osteoclasts and other target cells.
G protein-coupled receptors regulate critical intracellular processes such as ion transport and cellular metabolism. Ion transport plays important physiological roles in both bone and kidney, which are key targets for CT. However, little is Abbreviations: BAPTA-AM, 1,2-Bis-(2-aminophenoxy)ethane-N,N,NЈ,NЈ-tetraacetic acid tetra(acetoxymethyl)ester; [Ca 2ϩ ] i , cytosolic free Ca 2ϩ concentration; CPT-cAMP, 8-(4-chlorophenylthio)-cAMP; CT, calcitonin; CTR, CT receptor; EC 50 , concentration required to produce 50% of maximum effect; IBMX, isobutylmethylxanthine; indo-1 AM, indo-1 penta(acetoxymethyl)ester; K d , dissociation constant; LPA, lysophosphatidic acid; NHE, Na ϩ /H ϩ exchanger; SERCA, sarco-endoplasmic reticulum Ca 2ϩ -ATPase; TPA, 13-O-tetradecanoyl phorbol-13-acetate.
known about regulation of ion transport and metabolism by the C1a and CTR⌬e13 CTR isoforms. The purpose of this study was to determine the effects of CT on proton efflux from human embryonic kidney cells transfected with either the C1a or CTR⌬e13 isoform. We examined the ability of CT to modulate proton efflux and investigated underlying mechanisms and signaling pathways. Here, we report novel cellular responses to CT mediated specifically by the C1a receptor isoform.
Materials and Methods

Materials and solutions
␣-MEM (catalog no. 12571) buffered with HCO 3 Ϫ (26 mm), PBS (catalog no. 14040), FBS (catalog no. 26140), antibiotic solution (penicillin, 10,000 U/ml; streptomycin, 10,000 g/ml; Amphotericin, 25 g/ml, catalog no. 15240), trypsin solution (Ca 2ϩ and Mg 2ϩ free, 0.05% trypsin and 0.53 mm EDTA, catalog no. 25300), G418 (catalog no. 11811), HCO 3 Ϫ -and glucosefree DMEM (catalog no. 23800), and HCO 3 Ϫ -free MEM (catalog no. 41500 and catalog no. 41200) were obtained from Gibco Laboratories (Burlington, Ontario, Canada). Bovine albumin (fraction V, fatty acid free) was from Roche Molecular Biochemicals (Laval, Quebec, Canada; catalog no. 775835). DMEM (catalog no. D-7777), amiloride (catalog no. A-7410), bafilomycin A 1 (catalog no. B-1793), 8-(4-chlorophenylthio)-cAMP (CPT-cAMP) (catalog no. C-3912), isobutylmethylxanthine (IBMX, catalog no. I-5879), and lysophosphatidic acid (1-oleoyl-2-hydroxy-sn-glycero-3-phosphate) (LPA) (catalog no. L-7260) were obtained from Sigma (St. Louis, MO). Amiloride and CPT-cAMP were dissolved in standard superfusion medium just before use, whereas IBMX was dissolved in dimethylsulfoxide. Indo-1 penta(acetoxymethyl)ester (indo-1 AM, catalog no. I-1223), 1,2-bis-(2-aminophenoxy)ethane-N,N,NЈ,NЈ-tetraacetic acid tetra(acetoxymethyl) ester (BAPTA-AM, catalog no. B-6769), and thapsigargin (catalog no. T-7459) were obtained from Molecular Probes, Inc. (Eugene, OR). BAPTA-AM, indo-1 AM, and thapsigargin were dissolved in dimethyl sulfoxide and stored in aliquots at Ϫ20 C. Salmon CT was obtained from Bachem (Torrance, CA; catalog no. H-2260) or Rorer Pharmaceutical (Fort Washington, PA). Stock solutions of CT were prepared in 0.2% sodium acetate and 0.05% sodium chloride with 1 mg/ml bovine albumin and stored in aliquots at Ϫ80 C. 1-[6-((17␤-3-methoxyestra-1,3,5 (10)-trien-17-yl) amino)hexyl]-1H-pyrrole-2,5-dione (U-73122, catalog no. 662035), 1-[6-((17␤-3-methoxyestra-1,3,5 (10)-trien-17-yl)amino)hexyl]-2,5-pyrrolidinedione (U-73343 catalog no. 662041), bisindolylmaleimide I (2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)maleimide, catalog no. 203291), staurosporine (catalog no. 569397), and ionomycin (catalog no. 407952) were obtained from Calbiochem (San Diego, CA); and stock solutions of all these agents were prepared in dimethyl sulfoxide and stored in aliquots at -80 C. Cariporide (HOE 642) was generously provided by Aventis Pharma Deutschland GmbH (Frankfurt am Main, Germany). Cariporide was dissolved in water and stored in aliquots at Ϫ20 C. Stock solution of TPA (13-O-tetradecanoyl phorbol-13-acetate) was prepared in dimethyl sulfoxide and stored at Ϫ20 C. Standard superfusion medium, used in experiments monitoring proton efflux, was HCO 3 Ϫ -free MEM (catalog no. 41500) supplemented with HEPES (1 mm) and bovine albumin (1 mg/ml) and adjusted to 290 Ϯ 5 milliosmoles/liter with NaCl, and pH 7.30 Ϯ 0.02 with NaOH. Glucose-free superfusion medium was DMEM (catalog no. 23800) without glucose or HCO 3 Ϫ , supplemented with HEPES (1 mm), l-glutamine (2 mm), bovine albumin (1 mg/ml), and adjusted to 290 Ϯ 5 milliosmoles/liter and to pH 7.30 Ϯ 0.02. The buffering power of the superfusion solutions was determined over a pH range of 7.0 -7.3 at 37 C and found to be 1.4 Ϯ 0.1 mm/pH unit for standard medium and 1.3 Ϯ 0.1 mm/pH unit for glucose-free medium.
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Measurement of proton efflux
Cells adhering to the polycarbonate membranes were placed in microflow chambers and positioned above silicon-based potentiometric sensors, which can detect changes in extracellular pH of as little as 10 Ϫ3 units (Cytosensor microphysiometer, Molecular Devices, Sunnyvale, CA) (14) . Cells were continuously superfused at a rate of 100 l/min with medium at 37 C. Superfusion media with low buffering power were used to enhance the small alterations in pH o arising because of efflux of protons from cells. Each chamber was supplied with medium from one of two reservoirs by a computer-controlled valve. Test substances were directly introduced in superfusion medium, and changes in proton efflux were monitored. The lag time between a valve switch and the arrival of test solutions at the microflow chambers was 4 -5 sec.
Surface potential of each silicon sensor, corresponding to the extracellular pH (pH o ), was plotted as a voltage-time trace. At 37 C, 61 mV corresponds to 1 pH unit. To measure the rate of acidification (net cellular efflux of proton equivalents), fluid flow to cells was stopped periodically for 30 sec. During this time, acid accumulated in the microflow chamber (vol, 2.8 l) causing pH o to decrease. Measurement of acidification rate was obtained by linear least-squares fit to the slope of the pH o -time trace during the time when fluid flow to the cells was stopped. Net cellular efflux of proton equivalents (proton efflux) was calculated from the acidification rate, based on the buffering power of the superfusion solution and volume of the microflow chamber. In experiments examining the role of cytosolic Ca 2ϩ in CT-induced proton efflux, cells were loaded with BAPTA-AM (50 m in conditioned medium) for 30 min at 37 C before placement in microflow chambers. To test for possible nonspecific interactions with silicon sensors, cultures were lysed using detergent solution and then superfused with CT solution or test media.
Measurement of [Ca 2ϩ ] i
Cells expressing C1a, CTR⌬e13, or empty vector, were loaded with indo-1 by incubation in conditioned medium with indo-1 AM (2 m) for 30 min at 37 C. Cells were then washed and harvested by 1-min exposure to trypsin solution. Conditioned medium was added to inactivate trypsin; and subsequently, cells were sedimented and resuspended in HEPES-buffered MEM (catalog no. 41200). Aliquots of cell suspension were sedimented and resuspended in 2 ml of continuously stirred Na ϩ -HEPES buffer in a fluorometric cuvette maintained at 37 C. Test substances were added directly to the cuvette.
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Measurement of lactate efflux and glucose uptake
Extracellular lactate was measured using a spectrophotometric assay based on generation of NADH via catalytic action of lactate dehydrogenase (Sigma lactate assay kit, catalog no. 826). Cultures were incubated with CT or vehicle in serum-free ␣-MEM (catalog no. 12571) containing bovine albumin (1 mg/ml) in 5% CO 2 at 37 C. Samples of media (100 l) were collected for lactate determination; and, at the end of each experiment, cells were harvested for protein measurement.
Initial rates of glucose uptake by C1a cells were measured using radiolabeled 2-deoxyglucose, as described previously (16) . Briefly, cultures were incubated for 1 min at 23 C with 2-deoxy-d- [ 3 H]glucose (60 m, specific activity adjusted with unlabeled 2-deoxyglucose to 3.3 mCi/ mmol) in glucose-free transport buffer. Incubations were terminated by washing with ice-cold isosmotic Tris-sucrose solution and cells were harvested for protein determination and scintillation counting.
Data analysis and statistics
Proton efflux was normalized as a percentage of basal efflux in standard superfusion medium before addition of test substance or change of superfusion solution. This normalization compensated for differences in cell numbers among the chambers. Basal levels of [Ca 2ϩ ] i were determined 50 sec before application of test substance. Peak Ca 2ϩ responses were quantified as the maximum elevation of [Ca 2ϩ ] i above basal levels induced by the test substance. Results are presented as representative traces or as means Ϯ se of the number of samples indicated. Sigmoid curves were fit by nonlinear regression using Prism (GraphPad Software, Inc., San Diego, CA). Comparisons among means were performed by ANOVA followed by a Tukey-Kramer test for multiple comparisons. Differences were accepted as statistically significant at P Ͻ 0.05.
Results
Effects of CT on proton efflux
Proton efflux from HEK293 cells, stably transfected with the C1a receptor isoform, CTR⌬e13 isoform, or empty vector, was monitored using microphysiometry. Basal proton efflux in standard superfusion medium remained steady for periods of at least 6 h. In C1a cells, superfusion with CT (10 nm) caused a rapid biphasic increase in proton efflux characterized by an initial transient (which reached maximum in 1.5-3 min and lasted approximately 8 min) and a sustained plateau (which lasted for periods of at least 4 h) (Fig. 1A) . Treatment with vehicle did not cause any appreciable change in proton efflux. Because the CTR⌬e13 isoform binds CT with lower affinity than does the C1a isoform, higher concentrations of CT were used to test CTR⌬e13 cells. In contrast to its effect on C1a cells, CT (0.1-1 m) did not elicit detectable changes in proton efflux from either CTR⌬e13 cells (Fig. 1B) or control cells transfected with empty vector (Fig. 1C) .
In C1a cells, we investigated the dependence of the increase in proton efflux on CT concentration. Responses to lower concentrations of CT (1-100 pm) consisted of a plateau only. On the other hand, the response to higher concentrations of CT (Ն1 nm) included both an initial transient and sustained plateau ( Fig. 2A) . The initial phase of the CT response was quantified as the maximal increase in proton efflux above basal within 4.5 min of application of CT ( We then examined the effect of sequential applications of CT on proton efflux from C1a cells. Initial superfusion with a maximally effective concentration of CT (10 nm) caused a biphasic increase in proton efflux (initial phase, 91 Ϯ 16%; sustained plateau, 63 Ϯ 15%; n ϭ 7; Fig. 3 ). Subsequently, cells were superfused with standard medium for periods of 0.5-2.5 h. A second application of CT (10 nm) did not induce any additional increase in proton efflux, regardless of the time between challenges. These findings are in keeping with the poor reversibility of CT binding to its receptors. On the other hand, initial superfusion with a submaximal concentration of CT (10 pm) increased proton efflux to plateaus of 25 Ϯ 6% above basal (n ϭ 3). Subsequently, cells were superfused with standard medium for 30 min, after which application of CT (10 nm) elevated proton efflux (initial phase, 100 Ϯ 8% and sustained plateau, 76 Ϯ 5% above basal values calculated immediately before superfusion with 10 pm CT; n ϭ 3). The second response was not significantly different from the control response to CT (10 nm) in parallel samples of naive cells (initial phase, 86 Ϯ 10%; sustained plateau, 61 Ϯ 9%; n ϭ 4). Thus, no evidence was found for desensitization. 
Role of Na ϩ /H ϩ exchange in CT-induced proton efflux
Next, we investigated the mechanisms underlying the effects of CT on proton efflux from C1a cells. Na ϩ /H ϩ exchange is an important pathway for proton efflux and plays a role in the regulation of cytosolic pH, maintenance of cell volume, and transcellular Na ϩ transport. To assess the involvement of Na ϩ /H ϩ exchange, we first used amiloride, an inhibitor of the Na ϩ /H ϩ exchanger isoforms NHE-1, 2, and 5 (17, 18).
C1a cells were treated with amiloride (500 m) or vehicle in standard superfusion medium. Treatment with amiloride caused a slight decrease in proton efflux (to ϳ95% of basal levels). Subsequently, cells were treated with CT (10 nm) in the continued presence of amiloride or vehicle. Amiloride abolished the transient component of the initial phase of the CT response (Fig. 4A ). Cells were then superfused with either amiloride or vehicle, before returning to standard superfusion medium. A rapid overshoot in proton efflux was observed upon washout of amiloride. Subtracting the response to CT in the presence of amiloride from the control response revealed the amiloride-sensitive component (Fig. 4Aii) . This component accounts for the transient portion of the initial phase of the CT response. Consistent with the pattern observed in Fig. 4Aii , an increase in the set point of the Na ϩ /H ϩ exchanger, to a more alkaline value of cytosolic pH, causes a transient increase in proton efflux by the exchanger, lasting only until a new alkaline steady-state value is reached. Because amiloride inhibits several isoforms of the Na ϩ /H ϩ exchanger, we next used cariporide (HOE 642), a potent and highly selective inhibitor of NHE-1 (19) . Like amiloride, cariporide (5 m) abolished the initial transient but not the sustained plateau (Fig. 4B) . The cariporidesensitive component of the CT response was virtually identical to the amiloride-sensitive efflux (Fig. 4Bii) . Taken together, these data establish that the initial transient portion of the CT-stimulated increase in proton efflux from C1a cells is attributable to NHE-1 activity.
It has been previously shown that CT stimulates H ϩ secretion from rat kidney intercalated cells via a bafilomycin A 1 -sensitive mechanism (20) , likely the vacuolar H ϩ -ATPase. We used the specific inhibitor, bafilomycin A 1 , to examine the possible involvement of the vacuolar H ϩ -ATPase in CTinduced proton efflux. C1a cells were treated with bafilomycin (100 -500 nm) or vehicle in standard superfusion medium. Treatment with bafilomycin did not affect basal proton efflux. Proton efflux induced by 10 nm CT in the presence of bafilomycin A 1 (initial phase, 79 Ϯ 11%; sustained plateau, 38 Ϯ 3%; n ϭ 7) was not significantly different from responses in the presence of vehicle (initial phase, 65 Ϯ 5%; sustained plateau, 31 Ϯ 4%; n ϭ 8), arguing against a role for the vacuolar H ϩ -ATPase.
Dependence of CT-induced proton efflux on extracellular glucose
We next considered the possibility that the sustained plateau phase of the CT-induced increase in proton efflux is caused by enhanced metabolism of glucose. Parallel samples of C1a cells were superfused with standard medium (containing 5 mm glucose) or glucose-free medium. Superfusion with glucose-free medium rapidly decreased basal proton efflux to 43 Ϯ 5% of control levels (Fig. 5Ai , mean Ϯ se, n ϭ 8), indicating that basal efflux is highly sensitive to changes in the availability of glucose. Cells were then exposed to CT (10 nm) in the presence or absence of glucose. We observed that the removal of glucose virtually abolished the sustained plateau phase of the CT response, leaving the initial transient component intact. Upon reintroduction of glucose, proton efflux recovered to levels comparable with the sustained plateau in control cells exposed to CT in the presence of glucose (Fig. 5Aii) .
To confirm the role of extracellular glucose in the plateau phase of the CT response, parallel samples were treated with CT (1-30 nm) or vehicle. Subsequently, when both CT-and vehicle-treated cells were superfused with glucose-free medium (7.5-20 min), there was a large rapid decrease in proton efflux, to comparable levels (Fig. 5Bii) . Thus, the plateau phase is completely dependent on extracellular glucose, suggesting that glucose metabolism underlies this phase of the response to CT.
Based on its dependence on extracellular glucose, it is possible that lactic acid production plays a role in the sustained plateau phase of proton efflux. To investigate the effect of CT on lactic acid efflux, C1a cells were incubated with either CT (10 nm) or vehicle, and CTR⌬e13 cells were incubated with CT (1 m) or vehicle for 2 h. CT caused a significant increase in lactate efflux from C1a cells but had no significant effect on lactate efflux from CTR⌬e13 cells (Fig. 6) . The amplitude of the CT-induced increase in lactate efflux (ϳ50%) in C1a cells was comparable with that of the sustained increase in proton efflux (ϳ44%) induced by CT. Thus, the plateau phase of the CT-induced increase in proton efflux seems to arise by enhanced glycolysis. We next examined whether this effect involved enhanced glucose transport. CT had no significant effect on the initial rate of 2-deoxyglucose uptake (380 Ϯ 63 nmol [ in control cells; 358 Ϯ 69 nmol [ 3 H]deoxyglucose/g cell protein⅐min in cells pretreated with 10 nm CT for 15 min, mean Ϯ se, n ϭ 6 separate experiments). These findings indicate that CT-induced proton efflux does not arise simply from an increase in the rate of glucose uptake.
Role of cAMP in CT-induced increase in proton efflux
The EC 50 reported in our studies for the effect of CT on proton efflux is similar to the value reported previously for CT-mediated increases of cAMP levels in C1a cells (10) . However, although CT leads to elevation of cAMP in both C1a and CTR⌬e13 cells, it failed to induce an increase in proton efflux from CTR⌬e13 cells, arguing against a role for this second messenger in mediating CT-induced proton efflux from C1a cells.
To further investigate the involvement of cAMP in regulating proton efflux, we examined the effects of CPTcAMP (a membrane-permeable, phosphodiesterase-resistant analog of cAMP). Maximally effective concentrations of CPT-cAMP (0.1-1 mm) induced only a small increase in proton efflux from C1a cells, to 7 Ϯ 1% above basal (n ϭ 21). Moreover, CPT-cAMP had no significant effect on the subsequent response of C1a cells to CT (10 nm) ( Table 1) . Next, we examined the effects of the phosphodiesterase inhibitor, IBMX. IBMX (40 m) induced a small increase in proton efflux but did not potentiate the subsequent response of C1a cells to CT (1-10 nm) ( Table 1 ). Even at higher concentrations, IBMX did not potentiate the response to CT. In C1a cells treated with IBMX (0.1-1 mm), the increase in proton efflux induced by 1 nm CT (initial phase, 84 Ϯ 9%; sustained plateau, 58 Ϯ 6%; n ϭ 7) was not significantly different from the response to CT in vehicle-treated control cells (initial phase, 81 Ϯ 13%; sustained plateau, 56 Ϯ 7%; n ϭ 6). Taken together, these data suggest that elevation of cAMP does not underlie the CT-induced increase in proton efflux from C1a cells.
Effect of CT on the [Ca 2ϩ ] i
To further characterize the signaling pathways underlying the actions of CT on proton efflux from C1a cells, we next vector) and in CTR⌬e13 cells (Fig. 7Aii) . 1 These findings indicate that CT-induced changes in [Ca 2ϩ ] i are mediated selectively by the C1a receptor.
To confirm the responsiveness of CTR⌬e13 cells, we also examined effects of LPA, which acts through G proteincoupled receptors to evoke elevation of [Ca 2ϩ ] i in a number of target tissues (21) . In CTR⌬e13 cells previously exposed to CT, LPA (10 m) induced rapid elevation in [Ca 2ϩ ] i , to 656 Ϯ 74 nm above basal levels of 126 Ϯ 12 nm (Fig. 7Aii, n ϭ 18) . This finding establishes the presence of abundant intracellular Ca 2ϩ stores and cellular machinery supporting receptor-induced elevation of [Ca 2ϩ ] i and argues against the existence of a signal from the CTR⌬e13 receptor that inhibits Ca 2ϩ mobilization. Next, we examined the dependence of the amplitude of the Ca 2ϩ response on CT concentration (Fig. 7B) . The EC 50 for the effects of CT on elevation of [Ca 2ϩ ] i in C1a cells was 1-3 nm, similar to that reported for CT-induced production of inositol phosphates in C1a cells (10) We then investigated whether activation of phospholipase C played a role in the CT-induced elevation of [Ca 2ϩ ] i in C1a cells. Cells were pretreated with U-73122, a PLC inhibitor, or U-73343, an inactive analog (3 m, 10.5 min), and were resuspended in Na ϩ -HEPES buffer containing inhibitor or inactive analog. U-73122 virtually abolished the Ca 2ϩ response to CT, implicating PLC in this response. In contrast, after pretreatment with U-73343, CT (1 nm) induced an elevation in [Ca 2ϩ ] i similar to responses observed in untreated C1a cells ( Table 2) .
Elevation of cytosolic Ca 2ϩ suppresses proton efflux
C1a cells, but not CTR⌬e13 cells, respond to CT with large elevations in [Ca 2ϩ ] i , reflecting the selective effects of CT on proton efflux from C1a but not CTR⌬e13 cells. To test whether elevations in [Ca 2ϩ ] i mediate an increase in proton efflux, we used the Ca 2ϩ ionophore, ionomycin, and the sarco-endoplasmic reticulum Ca 2ϩ -ATPase (SERCA) inhibitor, thapsigargin. Ionomycin (100 nm) and thapsigargin (1 m) elevated [Ca 2ϩ ] i to 538 Ϯ 63 (mean Ϯ se, n ϭ 6) and 334 Ϯ 75 nm (n ϭ 7) above basal levels of 130 Ϯ 22 and 114 Ϯ 27 nm, respectively (Fig. 8A) , comparable with CT-induced elevations of [Ca 2ϩ ] i in C1a cells of 544 Ϯ 47 nm above basal levels of 163 Ϯ 15 nm.
Proton efflux from parallel samples of C1a cells was then monitored. Superfusion of cells with ionomycin (1 m) 2 or thapsigargin (1 m) induced a gradual decrease in proton efflux, to 26 Ϯ 2% and 37 Ϯ 21% below basal, respectively (n ϭ 3). Proton efflux returned slowly to basal levels after washout of ionomycin but not thapsigargin (Fig. 8B) . Our observation that ionomycin and thapsigargin suppressed, rather than enhanced, proton efflux suggests that elevation of [Ca 2ϩ ] i alone does not lead to the increase in proton efflux induced by CT.
To further assess the role of CT-induced elevation of [Ca 2ϩ ] i in proton efflux, we loaded cells with the intracellular Ca 2ϩ chelator, BAPTA. We have previously reported that loading C1a cells using BAPTA-AM (50 m, 30 min) reduced the amplitude of the elevation of [Ca 2ϩ ] i induced by CT (1 nm), from 319 Ϯ 37 nm to 53 Ϯ 4 nm above basal (13) . In the present study, C1a cells were loaded with BAPTA under the same conditions, and proton efflux in response to CT was monitored. CT-induced increases in proton efflux were still observed in BAPTA-loaded cells, indicating that a large elevation of [Ca 2ϩ ] i is not necessary for this response (data not shown).
Effect of PKC activation on proton and lactate efflux
In a number of tissues, PKC plays a role in agonistmediated activation of Na ϩ /H ϩ exchange and glycolysis (22) (23) (24) . Therefore, we investigated the possible role of PKC in mediating the CT-induced increase in proton and lactate efflux.
TPA is a potent activator of the conventional and novel PKC isoforms. In parallel samples of C1a cells, TPA (100 nm) caused a sustained increase in proton efflux, mimicking the plateau phase of the response to CT (Fig. 9A) . When vehicletreated control cells were subsequently treated with CT (10 nm), they responded with a biphasic elevation in proton efflux. However, in cells treated acutely with TPA, CT elicited the initial transient increase in proton efflux but no further increase in the sustained plateau phase. When both samples were treated again with TPA (100 nm), no additional increases in proton efflux were observed.
As a next step, we characterized the TPA-induced increase in proton efflux from C1a cells. When TPA-and vehicletreated cells were superfused with glucose-free medium, there was a rapid decrease in proton efflux, to comparable levels (Fig. 9B) . This finding indicates that, similar to the sustained plateau phase of the CT response, the sustained 2 A higher concentration of ionomycin was employed for the proton efflux experiments, because the standard medium contained bovine albumin (1 mg/ml), which bound ionomycin, reducing its apparent potency. increase in proton efflux induced by TPA is entirely dependent on extracellular glucose (compare Figs. 5B and 9B). Because CT failed to elicit an increase in proton or lactate efflux from CTR⌬e13 cells, we investigated the responsiveness of these cells to TPA. First, parallel samples of CTR⌬e13 cells were treated with CT (1 m) or vehicle. In both cases, subsequent application of TPA (100 nm) caused a sustained increase in proton efflux similar to that seen in C1a cells (after CT, 41 Ϯ 2% above basal, n ϭ 10; following vehicle, 61 Ϯ 11% above basal, n ϭ 2; Fig. 10A ). These data rule out the possibility that CT activates a signaling mechanism that inhibits PKC-induced proton efflux. We next examined the effects of TPA on lactate efflux from C1a and CTR⌬e13 cells. TPA (100 nm) stimulated lactate efflux from both C1a and CTR⌬e13 cells (Fig. 10B) . As shown in Fig. 6 , basal lactate efflux from CTR⌬e13 cells was considerably lower than that from C1a cells; however, the absolute effect of TPA on lactate efflux was almost as much in CTR⌬e13 cells as in C1a cells, indicating that the CTR⌬e13 cells are capable of increasing glycolysis in response to activation of PKC.
Taken together, these findings suggest the involvement of PKC in mediating the plateau phase of the CT-induced increase in proton efflux.
Effect of PKC inhibition or depletion on CT-induced increase in proton efflux
To further assess the role of PKC in the CT-induced increase in proton efflux, we first investigated the effect of the kinase inhibitor staurosporine. On its own, staurosporine (100 nm) did not affect basal proton efflux. However, staurosporine partially inhibited both the initial transient and the sustained plateau phase of the increase in proton efflux induced by CT (10 nm, Fig. 11A ). To confirm the effectiveness of staurosporine, we examined its effect on responses to TPA.
In vehicle-treated C1a cells, TPA increased proton efflux to plateaus of 27 Ϯ 5% above basal (mean Ϯ se, n ϭ 4). On the other hand, pretreatment with staurosporine (100 nm, 15 min) completely abolished the response to TPA, confirming its effectiveness (data not shown).
We next investigated the effect of bisindolylmaleimide I, a potent and more selective inhibitor of PKC (Fig. 11B) . Bisindolylmaleimide I (100 nm) reduced the CT-induced proton efflux by a relatively uniform amount at all times, consistent with partial inhibition of the sustained plateau phase. We also examined the effect of bisindolylmaleimide I on TPA-induced increase in proton efflux. Similar to staurosporine, bisindolylmaleimide I inhibited the effects of TPA on proton efflux (data not shown).
Last, PKC was depleted by chronic treatment with TPA (100 nm for at least 16 h). Depletion of PKC reduced the sustained plateau of the response to CT (10 nm) by approximately 75%, though having little or no effect on the initial transient (Fig. 12) . As expected, depletion of PKC virtually abolished subsequent responses to TPA. Taken together, these findings indicate a role for PKC in mediating the sustained plateau phase of CT response in C1a cells.
Discussion
Activation of the C1a CTR isoform increases proton efflux
CT caused a rapid increase in proton efflux from HEK293 cells stably transfected with the C1a CTR isoform but not the CTR⌬e13 isoform. This response consisted of an initial transient, usually maximal within 3 min, and a sustained plateau lasting for periods of at least 4 h. Such responses after activation of a G protein-coupled receptor have not been reported previously. The magnitude of the increase in proton efflux was dependent on the concentration of CT. Although the sustained plateau was observed in response to both low and high concentrations of CT, the transient component of the initial phase was observed clearly only at higher concentrations (Ն1 nm).
The plateau phase of the response remained sustained in the continued presence of CT and after wash out. After treatment with a maximal concentration of CT, no additional increase in proton efflux was observed in response to a subsequent treatment. A similar sustained response and refractoriness to subsequent challenge has been described for the activation of adenylyl cyclase by the CTR in T47D cells (25) . The sustained response in both cases is probably attributable to the nearly irreversible binding of CT to its receptor at physiological pH (3). Prolonged activation of signaling pathways downstream from the C1a isoform may also contribute to the sustained elevation of proton efflux. Internalization of the CTR (26) prevents responses to subsequent treatments with CT, and it is also possible that the internalized receptor continues to transduce signals, in turn maintaining the sustained increase in proton efflux.
Mechanisms underlying the effects of CT on proton efflux
Blockers of Na
ϩ /H ϩ exchange (amiloride and cariporide) had negligible effects on basal proton efflux, indicating little activity of the exchanger under resting conditions. In contrast, both the inhibitors abolished the initial transient component of the CT-induced proton efflux. CT seems to rapidly stimulate the exchanger, giving rise to a transient increase in proton efflux that lasts only until a more alkaline steady-state cytosolic pH is established. Use of the Cytosensor microphysiometer allowed us to resolve stimulation of Na ϩ /H ϩ exchange more rapidly than could be accomplished using conventional approaches. On washout of amiloride or cariporide from CT-treated samples, a transient overshoot in proton efflux occurred, consistent with the recovery of Na ϩ /H ϩ exchange activity. At the concentrations used in our studies, cariporide selectively blocks the NHE-1 isoform (19) , which is endogenously expressed in HEK293 cells. Taken together, these findings are consistent with NHE-1 mediating the initial transient component of the CT response. In the rabbit renal distal convoluted tubule, CT activates a latent HCO 3 Ϫ -dependent mechanism, to induce recovery of cytosolic pH after an acid load (27) . Under the conditions used in our studies, it is unlikely that HCO 3 Ϫ influx contributed to efflux of proton equivalents, because all the superfusion solutions used in the microphysiometer must be nominally HCO 3 Ϫ -free to avoid the production of gas bubbles. In HEK293 cells, basal proton efflux drops to approximately 50% on removal of extracellular glucose. In C1a cells, the sustained plateau, but not the initial transient, is dependent on extracellular glucose. On reintroduction of glucose, proton efflux recovers rapidly to levels comparable with those in control cells treated with CT in the presence of glucose. This indicates that signaling pathways downstream from the CTR have been activated in the absence of glucose, but the sustained plateau is manifested only upon reintroduction of extracellular glucose. Interestingly, CT increased both lactate efflux and proton efflux (during the sustained plateau) by approximately 50% above basal rates but did not alter the rate of glucose uptake. Thus, our data clearly demonstrate that the sustained plateau component of the CT response arises from an increased rate of glycolysis, leading to efflux of lactic acid, which may be mediated by a member of the family of monocarboxylate transporters. A recent study demonstrated that activation of heterologously expressed human CTRs leads to gradual acidification of the culture medium over a period of 1-3 d (28). Additionally, it has been shown that CT transiently increases proton efflux from neonatal mouse calvariae (29) . However, the mechanisms underlying these effects were not characterized in either study.
Signal transduction pathways mediating CT-induced proton efflux from C1a cells
The C1a receptor couples through multiple G proteins to modulate the adenylyl cyclase/PKA pathway and the PLC/Ca 2ϩ /PKC pathway. In contrast, the CTR⌬e13 isoform couples to the adenylyl cyclase/PKA pathway but not to the PLC/Ca 2ϩ /PKC pathway. It is possible that CT-induced activation of Na ϩ /H ϩ exchange in C1a cells is mediated by the ␣-subunit of a heterotrimeric G protein activated by C1a, but not CTR⌬e13, as shown for G␣ q and G␣13 in other systems (17) . Second-messenger-dependent signaling pathways may mediate the effects of CT on glycolysis and Na ϩ /H ϩ exchange. The lack of effect of CT on proton efflux from CTR⌬e13 cells indicates that cAMPdependent pathways do not mediate an increase in proton efflux. This was further confirmed by the small response to the cAMP analog CPT-cAMP and the inability of the phosphodiesterase inhibitor IBMX to potentiate CT responses in C1a cells.
Elevation of [Ca 2ϩ ] i activates NHE-1 in certain systems via a Ca 2ϩ /calmodulin site on the exchanger (17) . In our study, the EC 50 for the effect of CT on proton efflux was markedly less than its EC 50 PKC-mediated activation of proton production and efflux has been reported in other systems (22-24, 30 -32) . Several observations indicate that PKC underlies at least part of the sustained plateau phase of the CT response in C1a cells. First, TPA [a potent activator of the conventional and novel PKC isoforms (␣, ␤I, ␤II, ␥, ␦, ⑀, , and )] causes a sustained glucose-dependent increase in proton and lactate efflux, mimicking the plateau phase of the CT-response. Second, in cells treated chronically with TPA to deplete PKC, the sustained plateau phase of the CT response is markedly suppressed. Third, in cells treated acutely with TPA, CT evokes only a transient increase in proton efflux, without further increase in the plateau phase. Fourth, in C1a cells previously treated with CT, TPA fails to elicit any further increase in proton efflux. Thus, activation of PKC seems to underlie the sustained plateau phase of the response to CT. An alternative explanation is that TPA leads to desensitization of the CTR via PKC-mediated phosphorylation. However, this is unlikely because cells treated with TPA (acutely or chronically) still responded to CT with a transient increase in proton efflux (Figs. 9A and 12Ai) . Furthermore, CT induces full elevation of [Ca 2ϩ ] i in cells acutely treated with TPA (data not shown). Our findings are in keeping with previous reports showing that activation of PKC stimulates 6-phosphofructo-2-kinase activity, glycolysis, and lactate production in hepatocytes and fibroblasts (23, 24) . It is possible that the sustained plateau phase of the CT response is mediated by either Ca 2ϩ -sensitive or -insensitive PKC isoforms, because chelating cytosolic Ca 2ϩ with BAPTA does not reduce basal [Ca 2ϩ ] i in C1a cells (134 Ϯ 19 nm in control cells vs. 186 Ϯ 12 nm in BAPTAloaded cells, n ϭ 7). In this regard, both CT and TPA activate PKC␣ (a Ca 2ϩ -sensitive conventional PKC isoform) in a porcine renal tubule cell line that possesses native CTRs (33) .
The kinase inhibitor staurosporine and the more specific PKC inhibitor bisindolylmaleimide I partially inhibit the effects of CT on proton efflux. At the concentration used in our studies, staurosporine inhibits PKC (isoforms ␣, ␤I, ␤II, ␥, ␦, and ⑀), PKA, protein kinase G, CaM kinase, and myosin light chain kinase. Staurosporine partially inhibited both the initial transient and the sustained plateau of the CT response. On the other hand, bisindolylmaleimide I, a more potent and selective inhibitor of PKC (isoforms ␣, ␤I, ␤⌱⌱, ␥, ␦, and ⑀), primarily inhibited the plateau phase. These findings establish that a PKC-dependent pathway underlies, at least in part, the sustained plateau phase of the CT response. Though bisindolylmaleimide completely blocks the effects of TPA on proton efflux from C1a cells, it only partially inhibits the CT response, suggesting that, in addition to PKC, an as-yet-unidentified mechanism is also involved. 
